Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist

30. november 2016 oppdatert av: AstraZeneca

A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)

The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

2508

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Argentina
      • Buenos Aires, Argentina
        • Research Site
      • Caba, Argentina
        • Research Site
      • Ciudad Autónoma de Bs. As., Argentina
        • Research Site
      • Ciudad de Buenos Aires, Argentina
        • Research Site
      • Concepción del Uruguay, Argentina
        • Research Site
      • Corrientes, Argentina
        • Research Site
      • Córdoba, Argentina
        • Research Site
      • Florida, Argentina
        • Research Site
      • Godoy Cruz, Argentina
        • Research Site
      • La Plata, Argentina
        • Research Site
      • Mar del Plata, Argentina
        • Research Site
      • Mendoza, Argentina
        • Research Site
      • Ranelagh, Argentina
        • Research Site
      • Rosario, Argentina
        • Research Site
      • San Miguel de Tucuman, Argentina
        • Research Site
  • Canada
      • Quebec, Canada
        • Research Site
    • Alberta
      • Calgary, Alberta, Canada
        • Research Site
      • Sherwood Park, Alberta, Canada
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada
        • Research Site
    • New Brunswick
      • Moncton, New Brunswick, Canada
        • Research Site
    • Ontario
      • Burlington, Ontario, Canada
        • Research Site
      • Hamilton, Ontario, Canada
        • Research Site
      • Ottawa, Ontario, Canada
        • Research Site
      • Toronto, Ontario, Canada
        • Research Site
    • Quebec
      • Montreal, Quebec, Canada
        • Research Site
      • St Charles Borromee, Quebec, Canada
        • Research Site
  • Chile
      • Concepcion, Chile
        • Research Site
      • Quillota, Chile
        • Research Site
      • Santiago, Chile
        • Research Site
      • Talcahuano, Chile
        • Research Site
      • Valparaiso, Chile
        • Research Site
      • Viña del Mar, Chile
        • Research Site
  • Filippinene
      • Iloilo City, Filippinene
        • Research Site
      • Lipa City, Filippinene
        • Research Site
      • Quezon City, Filippinene
        • Research Site
  • Forente stater
    • Alabama
      • Andalusia, Alabama, Forente stater
        • Research Site
      • Birmingham, Alabama, Forente stater
        • Research Site
    • Arizona
      • Flagstaff, Arizona, Forente stater
        • Research Site
      • Glendale, Arizona, Forente stater
        • Research Site
      • Phoenix, Arizona, Forente stater
        • Research Site
      • Tucson, Arizona, Forente stater
        • Research Site
    • California
      • Alhambra, California, Forente stater
        • Research Site
      • Anaheim, California, Forente stater
        • Research Site
      • Beverly Hills, California, Forente stater
        • Research Site
      • Garden Grove, California, Forente stater
        • Research Site
      • Lakewood, California, Forente stater
        • Research Site
      • North Hollywood, California, Forente stater
        • Research Site
      • Northridge, California, Forente stater
        • Research Site
      • Palmdale, California, Forente stater
        • Research Site
      • Rancho Mirage, California, Forente stater
        • Research Site
      • Redondo Beach, California, Forente stater
        • Research Site
      • Rolling Hills Estate, California, Forente stater
        • Research Site
      • Sacramento, California, Forente stater
        • Research Site
      • Stockton, California, Forente stater
        • Research Site
      • Thousand Oaks, California, Forente stater
        • Research Site
      • Upland, California, Forente stater
        • Research Site
      • Ventura, California, Forente stater
        • Research Site
      • Walnut Creek, California, Forente stater
        • Research Site
      • Westminister, California, Forente stater
        • Research Site
      • Woodland, California, Forente stater
        • Research Site
    • Colorado
      • Centennial, Colorado, Forente stater
        • Research Site
      • Colorado Springs, Colorado, Forente stater
        • Research Site
      • Wheat Ridge, Colorado, Forente stater
        • Research Site
    • Florida
      • Celebration, Florida, Forente stater
        • Research Site
      • Fort Lauderdale, Florida, Forente stater
        • Research Site
      • Hialeah, Florida, Forente stater
        • Research Site
      • Homestead, Florida, Forente stater
        • Research Site
      • Jacksonville, Florida, Forente stater
        • Research Site
      • Lehigh Acres, Florida, Forente stater
        • Research Site
      • Miami, Florida, Forente stater
        • Research Site
      • Ocala, Florida, Forente stater
        • Research Site
      • Orlando, Florida, Forente stater
        • Research Site
      • Ormond Beach, Florida, Forente stater
        • Research Site
      • Virginia Gardens, Florida, Forente stater
        • Research Site
    • Georgia
      • Gainesville, Georgia, Forente stater
        • Research Site
      • Smyrna, Georgia, Forente stater
        • Research Site
    • Idaho
      • Eagle, Idaho, Forente stater
        • Research Site
    • Illinois
      • Shiloh, Illinois, Forente stater
        • Research Site
    • Kansas
      • Lenexa, Kansas, Forente stater
        • Research Site
    • Kentucky
      • Fort Mitchell, Kentucky, Forente stater
        • Research Site
    • Louisiana
      • Covington, Louisiana, Forente stater
        • Research Site
    • Maine
      • Bangor, Maine, Forente stater
        • Research Site
    • Michigan
      • Farmington Hills, Michigan, Forente stater
        • Research Site
      • Flint, Michigan, Forente stater
        • Research Site
      • Traverse City, Michigan, Forente stater
        • Research Site
    • Minnesota
      • Minneapolis, Minnesota, Forente stater
        • Research Site
    • Missouri
      • St Louis, Missouri, Forente stater
        • Research Site
    • Nevada
      • Las Vagas, Nevada, Forente stater
        • Research Site
    • New Jersey
      • Union, New Jersey, Forente stater
        • Research Site
    • New York
      • Bronx, New York, Forente stater
        • Research Site
    • North Carolina
      • Durham, North Carolina, Forente stater
        • Research Site
      • Wilmington, North Carolina, Forente stater
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Forente stater
        • Research Site
      • Columbus, Ohio, Forente stater
        • Research Site
      • Dayton, Ohio, Forente stater
        • Research Site
      • Middleburg Heights, Ohio, Forente stater
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater
        • Research Site
    • Oregon
      • Corvallis, Oregon, Forente stater
        • Research Site
      • Portland, Oregon, Forente stater
        • Research Site
    • Pennsylvania
      • Jefferson Hills, Pennsylvania, Forente stater
        • Research Site
      • Pittsburgh, Pennsylvania, Forente stater
        • Research Site
    • South Carolina
      • Indian Land, South Carolina, Forente stater
        • Research Site
    • South Dakota
      • Rapid City, South Dakota, Forente stater
        • Research Site
    • Tennessee
      • Knoxville, Tennessee, Forente stater
        • Research Site
    • Texas
      • Arlington, Texas, Forente stater
        • Research Site
      • Austin, Texas, Forente stater
        • Research Site
      • Boerne, Texas, Forente stater
        • Research Site
      • Dallas, Texas, Forente stater
        • Research Site
      • Houston, Texas, Forente stater
        • Research Site
      • San Antonio, Texas, Forente stater
        • Research Site
    • Utah
      • Midvale, Utah, Forente stater
        • Research Site
      • Murray, Utah, Forente stater
        • Research Site
    • Virginia
      • Fairfax, Virginia, Forente stater
        • Research Site
      • Falls Church, Virginia, Forente stater
        • Research Site
    • Wisconsin
      • Madison, Wisconsin, Forente stater
        • Research Site
      • Milwaukee, Wisconsin, Forente stater
        • Research Site
  • Japan
      • Asahi-shi, Japan
        • Research Site
      • Chiyoda-ku, Japan
        • Research Site
      • Chuo-ku, Japan
        • Research Site
      • Fukuoka-shi, Japan
        • Research Site
      • Himeji-shi, Japan
        • Research Site
      • Hiroshima-shi, Japan
        • Research Site
      • Itabashi-ku, Japan
        • Research Site
      • Kagoshima-shi, Japan
        • Research Site
      • Kishiwada-shi, Japan
        • Research Site
      • Kobe-shi, Japan
        • Research Site
      • Kokubunji-shi, Japan
        • Research Site
      • Matsue-shi, Japan
        • Research Site
      • Minato-ku, Japan
        • Research Site
      • Mizunami-shi, Japan
        • Research Site
      • Niigata-shi, Japan
        • Research Site
      • Obihiro-shi, Japan
        • Research Site
      • Oita-shi, Japan
        • Research Site
      • Ota-shi, Japan
        • Research Site
      • Sagamihara-shi, Japan
        • Research Site
      • Sakai-shi, Japan
        • Research Site
      • Sakaide-shi, Japan
        • Research Site
      • Sapporo-shi, Japan
        • Research Site
      • Sendai-shi, Japan
        • Research Site
      • Setagaya-ku, Japan
        • Research Site
      • Shibuya-ku, Japan
        • Research Site
      • Shinagawa-ku, Japan
        • Research Site
      • Sumida-ku, Japan
        • Research Site
      • Takamatsu-shi, Japan
        • Research Site
      • Toshima-ku, Japan
        • Research Site
      • Tsukubo-gun, Japan
        • Research Site
      • Yokohama-shi, Japan
        • Research Site
  • Polen
      • Aleksandrów Łódzki, Polen
        • Research Site
      • Białystok, Polen
        • Research Site
      • Bielsko Biala, Polen
        • Research Site
      • Bydgoszcz, Polen
        • Research Site
      • Bystra Śląska, Polen
        • Research Site
      • Gdańsk, Polen
        • Research Site
      • Gorzów Wlkp, Polen
        • Research Site
      • Karczew, Polen
        • Research Site
      • Katowice, Polen
        • Research Site
      • Koszalin, Polen
        • Research Site
      • Kraków, Polen
        • Research Site
      • Lubin, Polen
        • Research Site
      • Lublin, Polen
        • Research Site
      • Ostrów Wielkopolski, Polen
        • Research Site
      • Poznań, Polen
        • Research Site
      • Ruda Slaska, Polen
        • Research Site
      • Rzeszów, Polen
        • Research Site
      • Skierniewice, Polen
        • Research Site
      • Szczecin, Polen
        • Research Site
      • Tarnów, Polen
        • Research Site
      • Toruń, Polen
        • Research Site
      • Trzebnica, Polen
        • Research Site
      • Warszawa, Polen
        • Research Site
      • Wieluń, Polen
        • Research Site
      • Wroclaw, Polen
        • Research Site
      • Wrocław, Polen
        • Research Site
      • Zabrze, Polen
        • Research Site
      • Łódź, Polen
        • Research Site
      • Łęczna, Polen
        • Research Site
      • Żnin, Polen
        • Research Site
  • Romania
      • Bragadiru, Romania
        • Research Site
      • Brasov, Romania
        • Research Site
      • Bucharest, Romania
        • Research Site
      • Constanta, Romania
        • Research Site
      • Deva, Romania
        • Research Site
      • Iasi, Romania
        • Research Site
      • Timisoara, Romania
        • Research Site
  • Sverige
      • Goteborg, Sverige
        • Research Site
      • Luleå, Sverige
        • Research Site
      • Lund, Sverige
        • Research Site
  • Tyskland
      • Aschaffenburg, Tyskland
        • Research Site
      • Bamberg, Tyskland
        • Research Site
      • Berlin, Tyskland
        • Research Site
      • Bonn, Tyskland
        • Research Site
      • Frankfurt, Tyskland
        • Research Site
      • Frankfurt/Main, Tyskland
        • Research Site
      • Geesthacht, Tyskland
        • Research Site
      • Gelsenkirchen, Tyskland
        • Research Site
      • Hamburg, Tyskland
        • Research Site
      • Hannover, Tyskland
        • Research Site
      • Herford, Tyskland
        • Research Site
      • Leipzig, Tyskland
        • Research Site
      • Mainz, Tyskland
        • Research Site
      • München, Tyskland
        • Research Site
      • Neu-Isenburg, Tyskland
        • Research Site
      • Rostock, Tyskland
        • Research Site
      • Rüdersdorf, Tyskland
        • Research Site
      • Witten, Tyskland
        • Research Site
  • Ukraina
      • Chernivtsi, Ukraina
        • Research Site
      • Dnipropetrovsk, Ukraina
        • Research Site
      • Ivano-Frankivsk, Ukraina
        • Research Site
      • Kharkiv, Ukraina
        • Research Site
      • Kyiv, Ukraina
        • Research Site
      • Lutsk, Ukraina
        • Research Site
      • Mykolayiv, Ukraina
        • Research Site
      • Uzhgorod, Ukraina
        • Research Site
      • Vinnytsia, Ukraina
        • Research Site
      • Vinnytsya, Ukraina
        • Research Site
      • Zaporizhzhia, Ukraina
        • Research Site
      • Zaporozhye, Ukraina
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 75 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures
  2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1
  3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (>250µg fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1.
  4. Documented treatment with ICS and LABA for at least 3 months prior to Visit 1 with or without oral corticosteroids and additional asthma controllers. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. For ICS/LABA combination preparations, the mid-strength approved maintenance dose in the local country will meet this ICS criterion.

Exclusion criteria:

  1. Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)

  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
  4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Benralizumab 30 mg q.4 uker
Benralizumab administreres subkutant hver 4. uke
Biologisk: Benralizumab
Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
Eksperimentell: Benralizumab 30 mg q.8 uker
Benralizumab administrert subkutant hver 8. uke
Biologisk: Benralizumab
Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
Placebo komparator: Placebo
Placebo administrert subkutant
Biologisk: Placebo
Placebo subcutaneously on study week 0 until study week 52 inclusive.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.
Immediately following the first administration of study drug through Study Week 56.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
The annual exacerbation rate is based on unadjudicated annual exacerbation rate reported by the investigator in the eCRF.
Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Asthma symptoms during night time and daytime are recorded by the patient each morning and evening in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma). Baseline is defined as the average of data collected from the evening of study day -10 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.
Immediately following the first administration of study drug through Study Week 56.
Change in Asthma Rescue Medication Use
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Change from Baseline to Week 56 in number of Rescue medication use (puffs/day)
Immediately following the first administration of study drug through Study Week 56.
Home Lung Function Assessments Based on PEF
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Change from Baseline to Week 56 in Home lung function (morning and evening Peak expiratory flow [PEF])
Immediately following the first administration of study drug through Study Week 56.
Proportion of Nights With Awakening Due to Asthma
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Change from Baseline to Week 56 on Proportion of Nights with awakening due to asthma
Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.
Immediately following the first administration of study drug through Study Week 56.
Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of <=0.75 indicates well-controlled asthma, scores between 0.75 to <=1.5 indicate partly controlled asthma, and >1.5 indicates not well controlled asthma.
Immediately following the first administration of study drug through Study Week 56.
Number of Patients With >=1 Asthma Exacerbation
Tidsramme: Immediately following the first administration of study drug through Study Week 56
Immediately following the first administration of study drug through Study Week 56
Time to First Asthma Exacerbation
Tidsramme: Immediately following the first administration of study drug through Study Week 56
Immediately following the first administration of study drug through Study Week 56
Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations
Tidsramme: Immediately following the first administration of study drug through Study Week 56.
Annual rate of asthma exacerbations that are associated with an emergency room visit or a hospitalization (adjudicated)
Immediately following the first administration of study drug through Study Week 56.
Pharmacokinetics of Benralizumab
Tidsramme: Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60
Mean PK Concentration at each visit
Baseline, Week 4, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, Week 56, Week 60
Immunogenicity of Benralizumab
Tidsramme: Pre-treatment until end of follow-up
Anti-drug antibodies (ADA) responses at baseline and post baseline. Persistently positive is defined as positive at >=2 post-baseline assessments (with >=16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.
Pre-treatment until end of follow-up
Extent of Exposure
Tidsramme: Immediately following the first administration of study drug through Study Week 56
Extent of exposure is defined as the duration of treatment in days
Immediately following the first administration of study drug through Study Week 56
Mean Change From Baseline to Week 56 in AQLQ(S)+12
Tidsramme: Immediately following the first administration of study drug through Study Week 56
AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of >=0.5 are considered clinically meaningful.
Immediately following the first administration of study drug through Study Week 56
Change From Baseline to Week 56 in EQ-5D-5L VAS
Tidsramme: Immediately following the first administration of study drug through Study Week 56
EQ-5D-5L VAS is to rate current health status on a scale of 0-100, with 0 being the worst imaginable health state.
Immediately following the first administration of study drug through Study Week 56
Mean Work Productivity Loss Due to Asthma
Tidsramme: Immediately following the first administration of study drug through Study Week 56
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Work productivity loss is derived by sum of percentage of missed work due to asthma and product of percentage of actual working hours times degree of asthma affecting work productivity while working. Percentage of missed work due to asthma is calculated by number of hours missed work due to asthma divided by total number of hours missed work plus number of hours actually worked. This is only applicable to patients who were employed.
Immediately following the first administration of study drug through Study Week 56
Mean Productivity Loss Due to Asthma in Classroom
Tidsramme: Immediately following the first administration of study drug through Study Week 56
WPAI+CIQ (Work Productivity and Activity Impairment plus Classroom Impairment Questionnaire) contains 10 questions. Classroom productivity loss is derived by sum of percentage of missed classes due to asthma and product of percentage of actual hours attending classes times degree of asthma affecting classroom productivity. Percentage of missed classes due to asthma is calculated by number of hours missed classes due to asthma divided by total number of hours missed classes plus number of hours actually attending classes. This is only applicable for patients who took classes.
Immediately following the first administration of study drug through Study Week 56
Number of Participants That Utilized Health Care Resources
Tidsramme: Immediately following the first administration of study drug through Study Week 56
Immediately following the first administration of study drug through Study Week 56
Patient and Clinician Assessment of Response to Treatment
Tidsramme: Immediately following the first administration of study drug through Study Week 56
CGIC (clinician global impression of change), and PGIC (patient global impression of change) are overall evaluation of response to treatment, conducted separately by investigator and patient using a 7-point rating scale, ranging from 1 (Very much Improved), to 7 (Very much Worse). This endpoint was added after the second protocol amendment, thus not all patients had data to be analyzed.
Immediately following the first administration of study drug through Study Week 56

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

AstraZeneca

Etterforskere

  • Hovedetterforsker: Mark Fitzgerald, MD, PhD, Professor of Medicine, The Lung Centre, Gordon and Leslie Diamond Health Care Centre, Vancouver Canada

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. august 2013

Primær fullføring (Faktiske)

1. mars 2016

Studiet fullført (Faktiske)

1. mars 2016

Datoer for studieregistrering

Først innsendt

31. juli 2013

Først innsendt som oppfylte QC-kriteriene

31. juli 2013

Først lagt ut (Anslag)

2. august 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

25. januar 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. november 2016

Sist bekreftet

1. november 2016

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • D3250C00018

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere